

CIN: L15142RJ1991PLC006353

# **SARDA PROTEINS LTD.**

To,  
The Corporate Relationship Department  
The Bombay Stock Exchange Limited,  
P. J. Towers, Dalal Street, Fort,  
Mumbai – 400 001

**Date: November 8, 2024**

**Sub: Outcome of Board meeting:**  
**REF: Sarda Proteins Limited (Scrip Code: 519242):**

Dear Sir/Madam,

Please note that the meeting of the Board of Directors of the Company was held today, 8<sup>th</sup> November 2024. The Board of Directors approved the unaudited financial results for the quarter and half year ended on 30<sup>th</sup> September 2024 along with Cash Flow Statement and Assets Liability Statement.

The copy of unaudited financial results along with Limited Review Report is attached herewith.

The Board meeting started at 6.00 pm and was concluded at 7.00 pm.

Kindly take the same on record.

**For Sarda Proteins Limited**

**Chirag Thumar**  
**Director**  
**DIN: 10640822**

Encl: Unaudited Financial Results



# **S K AGARWAL & ASSOCIATES**

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

## **Limited Review Report Unaudited Standalone Quarterly Results**

To  
The Board of Directors  
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Half Year ended on 30<sup>th</sup> September, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates  
Chartered Accountants  
FRN: 014841C

CA Sushil Kumar Agarwal  
Partner  
M. No.: 403073  
UDIN : 24403073BKASTR6518  
Place : Bhiwadi  
Date : 08.11.2024



**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2024**

Rs. in Lakhs

Particulars	Quarter Ended on	Quarter Ended on	Corresponding Quarter Ended on	Half Year Ended on	Corresponding Half Year Ended on	Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I Revenue from operations	14.00	-	-	14.00	23.58	129.58
II Other Income	-	-	4.13	-	8.22	16.53
III Total Revenue (I+II)	14.00	-	4.13	14.00	31.80	146.11
IV Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchase of Stock -m- Trade	-	-	-	-	23.63	120.71
Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
Employee Benefit Expenses	1.14	4.22	2.62	5.36	5.36	14.56
Finance Cost	0.00	-	-	0.00	-	0.01
Depreciation and Amortisation Expenses	-	-	-	-	-	-
Other expenses	2.39	3.78	2.02	6.17	3.47	8.95
Total Expenses (IV)	3.53	8.01	4.64	11.54	32.56	144.23
Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.89
V Exceptional Items	-	-	-	-	-	-
VII Profit/(Loss) before Extraordinary Items and Tax (V-VI)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.89
VIII Extraordinary Items	-	-	-	-	-	-
IX Profit/(Loss) before Tax (V-VI)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.89
X Tax Expense						
(1) Current Tax	-	-	-	-	-	(0.05)
(2) Deferred Tax	-	-	-	-	-	-
XI Profit/(Loss) for the period from Continuing Operations (VII-VIII)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.94
XII Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XIII Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIV Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XV Profit/(Loss) for the period (IX+XII)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.94
XVI Other Comprehensive Income						
A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	10.47	(8.01)	(0.51)	2.46	(0.76)	1.94
XVII Paid up Equity Share Capital (Face Value of the Share-Rs 10 Per Share)	172.59	172.59	172.59	172.59	172.59	172.59
XVIII Earnings per Equity Share						
(1) Basic	0.61	(0.46)	(0.03)	0.14	(0.04)	0.11
(2) Diluted	0.61	(0.46)	(0.03)	0.14	(0.04)	0.11

**Notes:**

- The above results were approved by Audit Committee in their meeting held on 08th November 2024 and by Board of Directors in their meeting held on 08th November 2024.
- Equity Share Capital includes Rs 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable, as company dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 30-Sep-2024 nor any pending as on 01-Oct-2024.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For S K Agarwal & Associates  
 Chartered Accountants  
 FRN 014841C

CA Sushil Kumar Agarwal  
 Partner  
 M No: 403073  
 Date: 08.11.2024  
 Place: Bhiwadi  
 UDIN: 24403073BKASTR6518

For and on behalf of Board  
 Sarda Proteins Ltd  
 CIN: L15142RJ1991PLC006353

Chirag Shantilal Thumar  
 Director  
 DIN: 10640822



**SARDA PROTEINS LTD**

CIN: L15142RJ1991PLC006353

Regd. Off.: B-536-537, Matsya Industrial Area, Alwar, Rajasthan- 301030

**Statement of Assets and Liabilities**

As at 30th September, 2024

(Rs. In Lakhs)

Particulars	Half Year Ended		Year Ended
	As at 30.09.2024	As at 30.09.2023	As at 31.03.2024
	Un-Audited	Un-Audited	Audited
<b>1 ASSETS</b>			
<b>Non- Current Assets</b>			
a) Property, Plant and Equipment	-	0.01	0.01
b) Financial Assets			
(i) Investments	-	0.13	-
(ii) Loans & Advances	-	-	-
c) Deferred Tax Assets (Net)	13.55	13.49	13.55
d) Other Non- Current Assets	-	-	-
<b>Total Non-Current Assets</b>	<b>13.55</b>	<b>13.63</b>	<b>13.56</b>
<b>Current Assets</b>			
a) Inventories	-	-	-
b) Financial Assets			
(i) Trade Receivables	16.52	-	-
(ii) Cash and Cash Equivalents	23.19	6.29	11.87
(iii) Loans & Advances	185.00	205.00	218.04
(iv) Others	2.62	13.00	-
<b>Total Current Assets</b>	<b>227.33</b>	<b>224.29</b>	<b>229.91</b>
<b>TOTAL ASSETS</b>	<b>240.88</b>	<b>237.92</b>	<b>243.47</b>
<b>2 EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
a) Share Capital	250.45	250.45	250.45
b) Other Equity (Reserve & Surplus)	(10.69)	(15.86)	(13.16)
<b>Total Equity</b>	<b>239.76</b>	<b>234.59</b>	<b>237.29</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
a) Financial Liabilities	-	-	-
b) Provisions	-	3.24	4.34
<b>Total Non-Current Liabilities</b>	<b>-</b>	<b>3.24</b>	<b>4.34</b>
<b>Current Liabilities</b>			
a) Financial Liabilities			
(i) Borrowings	-	-	-
(ii) Trade Payables	0.07	0.21	-
(iii) Other Financial Liabilities	-	-	1.84
b) Other Current Liabilities	1.05	(0.12)	-
<b>Total Current Liabilities</b>	<b>1.12</b>	<b>0.09</b>	<b>1.84</b>
<b>Total liabilities</b>	<b>1.12</b>	<b>3.33</b>	<b>6.18</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>240.88</b>	<b>237.92</b>	<b>243.47</b>

For S K Agarwal & Associates  
Chartered Accountants  
FRN: 014841C

CA Sushil Kumar Agarwal  
Partner  
M. No.: 403073  
Date : 08.11.2024  
Place : Bhiwadi  
UDIN: 24403073BKASTR6518



For and on behalf of Board  
Sarda Proteins Ltd  
CIN: L15142RJ1991PLC006353

Chirag Shantilal Thumar  
Director  
DIN: 10640822

**SARDA PROTEINS LTD**

CIN: L15142RJ1991PLC006353

Regd. Off.: B-536-537, Matsya Industrial Area, Alwar, Rajasthan- 301030

**Cash Flow Statement  
For the year ended 31st March 2024**

(Rs. In Lakhs)

Particulars	Half Year Ended		Year Ended
	As at 30.09.2024	As at 30.09.2023	As at 31.03.2024
	Un-Audited	Un-Audited	Audited
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Net Profit before Tax and extraordinary items	2.46	(0.76)	1.89
<b>A. ADJUSTMENT FOR</b>			
Depreciation	-	-	-
Interest Received	-	(8.22)	(16.53)
Profit on sale of Investment	-	-	0.13
Dividend	-	-	-
(Profit) /Loss on sale of Fixed Assets	0.01	-	-
Interest Paid	-	-	0.01
<b>Operating profit/(Loss) before working capital charges</b>	<b>2.48</b>	<b>(8.98)</b>	<b>(14.51)</b>
<b>ADJUSTMENT FOR:</b>			
Trade and other receivables	(16.52)	-	(9.67)
Other Current Assets/Liabilities	25.29	(11.84)	-
Trade & other Payables	0.07	-	1.09
Other Non Current Assets	-	0.45	-
<b>Cash generated from operations</b>	<b>11.32</b>	<b>(20.37)</b>	<b>(23.09)</b>
Direct Taxes Paid	-	-	-
<b>Net Cash from operating activities</b>	<b>11.32</b>	<b>(20.37)</b>	<b>(23.09)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>			
Capital Expenditure	-	-	-
Sale of Fixed Assets	0.01	-	-
Profit on sale of Investment/Fixed Asset	(0.01)	-	(0.13)
Sale of Investment	-	-	0.13
Interest received	-	8.22	16.53
Dividend received	-	-	-
<b>Net cash received from investing activities</b>	<b>(0.00)</b>	<b>8.22</b>	<b>16.53</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from Long term borrowings	-	-	-
Proceeds from Short term borrowings	-	-	-
Interest paid	-	-	0.01
<b>Net cash inflow/(outflow) from financing activities</b>	<b>-</b>	<b>-</b>	<b>0.01</b>
<b>Net cash increase/(Decrease) in cash and cash equivalents (A+B+C)</b>	<b>11.32</b>	<b>(12.15)</b>	<b>(6.56)</b>
<b>Cash &amp; Cash Equivalents (Opening)</b>	<b>11.87</b>	<b>18.44</b>	<b>18.43</b>
<b>Cash &amp; Cash Equivalents (Closing)</b>	<b>23.19</b>	<b>6.29</b>	<b>11.87</b>

For S K Agarwal & Associates  
Chartered Accountants  
FRN: 014841CCA Sushil Kumar Agarwal  
Partner

M. No.: 403073

Date : 08.11.2024

Place : Bhiwadi

UDIN: 24403073BKASTR6518

For and on behalf of Board  
Sarda Proteins Ltd  
CIN: L15142RJ1991PLC006353Chirag Shantilal Thumar  
Director  
DIN: 10640822